Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database

Digestive and Liver Disease

Volumn 48, Issue 11, 2016, Pages 1302-1307

  Kurti, Zsuzsanna ^a   Vegh, Zsuzsanna ^a   Golovics, Petra A ^a   Fadgyas Freyler, Petra ^b   Gecse, Krisztina B ^a   Gonczi, Lorant ^a   Gimesi Orszagh, Judit ^b   Lovasz, Barbara D ^a   Lakatos, Peter L ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b National Health Insurance Fund Administration OEP   (Hungary)

Author keywords

Drug treatment strategy; Epidemiology; Inflammatory bowel disease; Prevalence; Public health registry data

Indexed keywords

BIOLOGICAL PRODUCT; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MESALAZINE;

ADOLESCENT; ADULT; ARTICLE; BIOLOGICAL THERAPY; CHILD; COMBINATION DRUG THERAPY; CORTICOSTEROID THERAPY; CROHN DISEASE; FEMALE; GROUPS BY AGE; HUMAN; HUNGARY; ICD-10; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; ULCERATIVE COLITIS; AGE DISTRIBUTION; AGED; CLASSIFICATION; FACTUAL DATABASE; INFANT; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; NEWBORN; OUTPATIENT; PRESCHOOL CHILD; PUBLIC HEALTH; SEX RATIO; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HUNGARY; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OUTPATIENTS; SEX DISTRIBUTION; YOUNG ADULT;

EID: 84992494143     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.07.012     Document Type: Article

References (36)

1. [1] Molodecky, N.A., Soon, I.S., Rabi, D.M., et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142 (2012), 46–54.
2. [2] Gheorghe, C., Pascu, O., Gheorghe, L., et al. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. European Journal of Gastroenterology and Hepatology 16 (2004), 1153–1159.
3. [3] Vind, I., Riis, L., Jess, T., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population-based study from the Danish Crohn colitis database. American Journal of Gastroenterology 101 (2006), 1274–1282.
4. [4] Lindberg, E., Jörnerot, G., The incidence of Crohn's disease is not decreasing in Sweden. Scandinavian Journal of Gastroenterology 26 (1991), 495–500.
5. [5] Burisch, J., Jess, T., Martinato, M., et al. ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis 7 (2013), 322–337.
6. [6] Shivananda, S., Lennard-Jones, J., Logan, R., et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 39 (1996), 690–697.
7. [7] Burisch, J., Pedersen, N., Čuković-Čavka, S., et al. East–west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 63 (2014), 588–597.
8. [8] Vegh, Z., Burisch, J., Pedersen, N., et al. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. Journal of Crohn's and Colitis 8 (2014), 1506–1515.
9. [9] Sincić, B.M., Vucelić, B., Persić, M., et al. Incidence of inflammatory bowel disease in Primorsko-goranska County, Croatia, 2000–2004: a prospective population-based study. Scandinavian Journal of Gastroenterology 41 (2006), 437–444.
10. [10] Pezerović, D., Klarin, I., Zulj, M., et al. Incidence and prevalence of inflammatory bowel disease in Vukovarsko-Srijemska County, Croatia, 1991–2000 and 2001–2010: a population-based study. Collegium Antropologicum 38 (2014), 115–123.
11. [11] Lakatos, L., Lakatos, P.L., Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?. Postgraduate Medical Journal 82 (2006), 332–337.
12. [12] Lakatos, L., Kiss, L.S., David, G., et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002–2006. Inflammatory Bowel Diseases 17 (2011), 2558–2565.
13. [13] Lakatos, P.L., Golovics, P.A., David, G., et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977–2009. American Journal of Gastroenterology 107 (2012), 579–588.
14. [14] Gregus, M., The incidence and prevalence of IBD in Slovakia. Oral presentation. Czech and Slovak IBD conference, Prague, 2014.
15. [15] Bernstein, C.N., Wajda, A., Svenson, L.W., et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. American Journal of Gastroenterology 101 (2006), 1559–1568.
16. [16] Jussila, A., Virta, L.J., Salomaa, V., et al. High and increasing prevalence of inflammatory bowel disease in Finland with a clear North-South difference. Journal of Crohn's and Colitis 7 (2013), 256–262.
17. [17] Azevedo, L.F., Magro, F., Portela, F., et al. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach. Pharmacoepidemiology and Drug Safety, 19, 2010.
18. [18] Domenicantonio, R., Cappai, G., Arca, M., et al. Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. Digestive and Liver Disease 46 (2014), 777–782.
19. [19] Busch, K., Ludvigsson, J.F., Ekström-Smedby, K., et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Alimentary Pharmacology and Therapeutics 39 (2014), 57–68.
20. [20] Benchimol, E.I., Manuel, D.G., Guttmann, A., et al. Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflammatory Bowel Diseases 20 (2014), 1761–1769.
21. [21] Ng, S.C., Epidemiology of inflammatory bowel disease: focus on Asia. Best Practice and Research. Clinical Gastroenterology 28 (2014), 363–372.
22. [22] Ng, S.C., Tang, W., Ching, J.Y., et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn's and colitis epidemiology study. Gastroenterology 145 (2013), 158–165.
23. [23] Dignass, A., Van Assche, G., Lindsay, J.O., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis 4 (2010), 28–62.
24. [24] Ford, A.C., Kane, S.V., Khan, K.J., et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. American Journal of Gastroenterology 106 (2011), 617–629.
25. [25] Niewiadomski, O., Studd, C., Hair, C., et al. Health care cost analysis in a population based inception cohort of inflammatory bowel disease patients in the first year of diagnosis. Journal of Crohn's and Colitis 9 (2015), 988–996.
26. [26] Cars, T., Wettermark, B., Löfberg, R., et al. Healthcare utilization and drug treatment in a large cohort of patients with inflammatory bowel disease. Journal of Crohn's and Colitis 10 (2016), 556–565.
27. [27] Duricova, D., Pedersen, N., Elkjaer, M., et al. 5-Aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study. Journal of Crohn's and Colitis 4 (2010), 575–581.
28. [28] van der Valk, M.E., Mangen, M.J., Leenders, M., et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut 63 (2014), 72–79.
29. [29] Rencz, F., Péntek, M., Bortlik, M., et al. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World Journal of Gastroenterology 21 (2015), 1728–1737.
30. [30] Lakatos, P.L., David, G., Pandur, T., et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977–2008. Journal of Crohn's and Colitis 5 (2011), 5–13.
31. [31] Lovasz, B.D., Lakatos, L., Horvath, A., et al. Incidence rates and disease course of paediatric inflammatory bowel diseases in Western Hungary between 1977 and 2011. Digestive and Liver Disease 46 (2014), 405–411.
32. [32] Charpentier, C., Salleron, J., Savoye, G., et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 63 (2014), 423–432.
33. [33] Benchimol, E.I., Guttmann, A., Mack, D.R., et al. Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada. Journal of Clinical Epidemiology 67 (2014), 887–896.
34. [34] Bernstein, C.N., Blanchard, J.F., Rawsthorne, P., et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. American Journal of Epidemiology 149 (1999), 916–924.
35. [35] Betteridge, J.D., Armbruster, S.P., Maydonovitch, C., et al. Inflammatory bowel disease prevalence by age, gender, race, and geographic location in the U.S. military health care population. Inflammatory Bowel Diseases 19 (2013), 1421–1427.
36. [36] Kappelman, M.D., Rifas-Shiman, S.L., Kleinman, K., et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clinical Gastroenterology and Hepatology 5 (2007), 1424–1429.